Italfarmaco entrusts Maxer with the 2022 CTD programme

We are pleased to announce that Italfarmaco S.p.A. has entrusted Maxer Consulting with implementing the Clinical Trial Disclosure (CTD) programme for 2022.

CTD’s activities require Maxer to ensure Italfarmaco’s compliance by posting the results of the clinical trials according to the regulations in force in the European Union and the United States. The results will be published respectively on the EudraCT and PRS platforms.